What question did this study set out to answer?

To compare the glycemic efficacy and safety of two adjusted glibenclamide dosing regimens in fasting individuals with non-insulin dependent diabetes against non-fasting controls during Ramadan.

July 31, 1993BMJOpen Access

Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide.

View Full Paper

Ask AI

Bookmark

Authors

JBJamal BelkhadirDirection de l’Epidémiologie et de Lutte contre les Maladies HGH. El GhomariAssociation Marocaine Pour la Recherche Développement NKNikolaj KlöckerDüsseldorf University Hospital

Discussion

Member takes

Implication

Randomized trial demonstrates stable glycemic control and low hypoglycemia risk across glibenclamide regimens in fasting diabetic patients, indicating adjusted dosing safely supports Ramadan fasting.

Key Points

To compare the glycemic efficacy and safety of two adjusted glibenclamide dosing regimens in fasting individuals with non-insulin dependent diabetes against non-fasting controls during Ramadan.
Conducted across five clinical centers in Morocco, recruiting 591 diabetic patients (198 men, 391 women; 542 completed the study).
Assigned participants to a non-randomized non-fasting control group receiving standard glibenclamide or randomized fasting groups taking morning doses at sunset and evening doses before dawn at either full dose or a 25% dose reduction.
Tracked serum fructosamine concentrations, total glycated hemoglobin percentages, and the incidence of hypoglycemic episodes across all groups.
Serum fructosamine concentrations showed no significant differences between groups at the end of Ramadan, measuring 400 µmol/L in controls, 381 µmol/L in the full-dose fasting group, and 376 µmol/L in the reduced-dose fasting group.
Total glycated hemoglobin levels showed no significant differences between the non-fasting controls (14.7%), the full-dose fasting cohort (14.0%), and the reduced-dose fasting cohort (13.6%).
Documented hypoglycemic events were low and did not significantly differ between the control arm (11 events), the full-dose fasting arm (14 events), and the reduced-dose fasting arm (10 events).

Cite This Study

Belkhadir et al. (1993) studied this question.

synapsesocial.com/papers/6a7628b59aebbbed3661475c https://doi.org/10.1136/bmj.307.6899.292

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates stable glycemic control and low hypoglycemia risk across glibenclamide regimens in fasting diabetic patients, indicating adjusted dosing safely supports Ramadan fasting.

Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide.

Discussion

Member takes

Implication

Key Points

Cite This Study

Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider